← Leaderboards
Robert Keith Naviaux
University Of California San Diego
$394,130
Attributed
$394,130
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $202.5K · FY2005–10$250K$187.5K$125K$62.5K$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$394,130 · 5
By mechanism
R21$376,339 · 1
R13$16,000 · 1
M01$1,791 · 3
Top collaborators
No co-investigators on record.
Most similar at University Of California San Diego
Same institution · by research overlap
- William L. Nyhan$92,539
- Andrea L Hevener$13,659,300
- Jerry A Schneider$14,686
- Alice L. Yu$1,929,330
- W D Parker$1,138,133
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectMitochondrial Disease /DisorderProgramsMetabolism Disorder ChemotherapyHuman Therapy EvaluationLeadMitochondriaUridineBaseCessation Of LifeCellsChildChild (0-11)Autistic DisorderAnimal ModelCatalytic DomainDeoxyriboseDefectBrain DiseasesDiagnosisDisease-Causing MutationDisease /Disorder Proneness /RiskArea
Grant awards (23)
MITOCHONDRIA AND AUTISM 2010$16,000
R13 · FY2010 · NS · contact PI
A MOUSE MODEL OF ALPERS SYNDROME$202,526
R21 · FY2007 · NS · contact PI
A MOUSE MODEL OF ALPERS SYNDROME$173,813
R21 · FY2006 · NS · contact PI
TRIACETYLURIDINE MAINTENANCE THERAPY OF MITOCHONDRIAL DISEASE$610
M01 · FY2005 · RR
Triacetyluridine Therapy of Mitochondrial Disease$1,181
M01 · FY2004 · RR
URIDINE &TRIACETYLURIDINE FOR MITOCHONDRIAL DISEASE$0
M01 · FY2002 · RR
URIDINE &TRIACETYLURIDINE FOR MITOCHONDRIAL DISEASE$0
M01 · FY2002 · RR
URIDINE &TRIACETYLURIDINE FOR MITOCHONDRIAL DISEASE$0
M01 · FY2002 · RR
URIDINE &TRIACETYLURIDINE FOR MITOCHONDRIAL DISEASE$0
M01 · FY2002 · RR
MANIFESTATIONS OF MITOCHONDRIAL DISEASE$0
M01 · FY2002 · RR
MANIFESTATIONS OF MITOCHONDRIAL DISEASE$0
M01 · FY2002 · RR
MANIFESTATIONS OF MITOCHONDRIAL DISEASE$0
M01 · FY2002 · RR
MANIFESTATIONS OF MITOCHONDRIAL DISEASE$0
M01 · FY2002 · RR
MANIFESTATIONS OF MITOCHONDRIAL DISEASE$0
M01 · FY2001 · RR
URIDINE &TRIACETYLURIDINE FOR MITOCHONDRIAL DISEASE$0
M01 · FY2001 · RR
URIDINE &TRIACETYLURIDINE FOR MITOCHONDRIAL DISEASE$0
M01 · FY2001 · RR
MANIFESTATIONS OF MITOCHONDRIAL DISEASE$0
M01 · FY2001 · RR
URIDINE &TRIACETYLURIDINE FOR MITOCHONDRIAL DISEASE$0
M01 · FY2000 · RR
MANIFESTATIONS OF MITOCHONDRIAL DISEASE$0
M01 · FY2000 · RR
URIDINE &TRIACETYLURIDINE FOR MITOCHONDRIAL DISEASE$0
M01 · FY2000 · RR
MANIFESTATIONS OF MITOCHONDRIAL DISEASE$0
M01 · FY2000 · RR
MANIFESTATIONS OF MITOCHONDRIAL DISEASE$0
M01 · FY2000 · RR
URIDINE &TRIACETYLURIDINE FOR MITOCHONDRIAL DISEASE$0
M01 · FY2000 · RR